Summary："Breakthrough Preclinical Results Unveiled for Revolutionary Leukemia Vaccine Treatment"COPENHAGEN,

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

"Breakthrough Preclinical Results Unveiled for Revolutionary Leukemia Vaccine Treatment"

COPENHAGEN, Denmark, June 11, 2026 - In a groundbreaking development, Evaxion A/S (NASDAQ: EVAX), a pioneering TechBio company specializing in the development of novel vaccines through its AI-Immunology™ platform, has announced unprecedented preclinical results for EVX-04, a cutting-edge, off-the-shelf therapeutic vaccine designed to combat leukemia.

The latest findings, unveiled today, signify a major leap forward in the fight against leukemia, a disease that continues to claim countless lives worldwide. Evaxion's EVX-04 vaccine has demonstrated remarkable efficacy in preclinical trials, showcasing its potential to revolutionize current treatment paradigms for leukemia patients. By harnessing the power of the company's proprietary AI-Immunology™ platform, Evaxion has successfully identified and targeted specific leukemia-associated antigens, thereby eliciting a robust and highly specific immune response.

Industry experts are abuzz with excitement over the implications of these results, as they underscore the vast potential of immunotherapy in oncology. The success of EVX-04 in preclinical settings not only validates Evaxion's innovative approach but also highlights the growing importance of AI-driven technologies in vaccine development. As the global oncology vaccine market continues to expand, driven by an increasing prevalence of cancer and a pressing need for more effective treatments, Evaxion is poised to make a significant impact.

Looking ahead, Evaxion is expected to rapidly advance EVX-04 into clinical trials, with the aim of translating these promising preclinical results into tangible clinical benefits for leukemia patients. As the company progresses towards this goal, its achievements are likely to attract considerable attention from investors, healthcare professionals, and patients alike.

In conclusion, Evaxion's unveiling of breakthrough preclinical results for EVX-04 marks a significant milestone in the quest to develop more effective treatments for leukemia. With its innovative AI-Immunology™ platform and a robust pipeline of novel vaccines, Evaxion is at the forefront of a new era in immunotherapy, offering renewed hope to patients and families affected by this devastating disease.